Topic: How To Invest

Pat: What do you think of Knight Therapeutics and Aurora Spine Corp.? Thank you.

Article Excerpt

Knight Therapeutics, $5.45, symbol GUD on Toronto (Shares outstanding: 77.8 million; Market cap: $423.8 million; www.gud-knight.com), was handed out to Paladin Labs shareholders after that company was recently acquired by Endo Health Solutions plc. Knight began trading on the Toronto exchange on March 3, 2014. The company’s assets from the spinoff mostly consist of Impavido, for treating Leishmaniasis, a rare disease that is spread via bites from infected sand flies. The U.S. Food and Drug Administration approved Impavido on March 19, 2014. Knight Therapeutics has just raised $180.1 million by issuing special warrants for $5.25 each. These warrants can be converted into common shares by August 11, 2014. Earlier this year, the company raised an additional $75 million. The company is run by Jonathan Goodman, Paladin’s co-founder and former CEO. Goodman now aims to repeat his success at Paladin by following the same business model. Paladin mainly bought, licensed and marketed drugs, with a focus on treatments with patents that were about to expire,…